Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 62, Issue 10, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01299-18
Keywords
HIV-2; PrEP; West Africa; antiretroviral therapy; cabotegravir; human immunodeficiency virus; treatment
Categories
Funding
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [2R01-AI060466, R01-AI120765]
- UW Center For AIDS Research (CFAR, an NIH) [P30 AI027757]
- UW Royalty Research Fund [A92723]
- U.S. National Institutes of Health
- University of Washington
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Alere Technologies
- Merck Co., Inc.
- Janssen Pharmaceutica
- Cerus Corporation
- ViiV Healthcare
- Abbott Molecular Diagnostics
- Mary Gates Endowment for Students (University of Washington)
- National Institutes of Health/National Institute of Allergy and Infectious Diseases
- France REcherche Nord & Sud Sida-hiv Hepatites (ANRS)
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120765, R01AI060466, P30AI027757] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC(50)s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
